Pliant Therapeutics’ (PLRX) “Neutral” Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald restated their neutral rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) in a report published on Tuesday, Marketbeat Ratings reports. Cantor Fitzgerald also issued estimates for Pliant Therapeutics’ FY2025 earnings at ($1.51) EPS. Other research analysts have also issued research reports about the stock. Canaccord Genuity Group restated a “hold” rating […]
Cantor Fitzgerald restated their neutral rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) in a report published on Tuesday, Marketbeat Ratings reports. Cantor Fitzgerald also issued estimates for Pliant Therapeutics’ FY2025 earnings at ($1.51) EPS. Other research analysts have also issued research reports about the stock. Canaccord Genuity Group restated a “hold” rating […]
